While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...

Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.

The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer's, chronic respiratory ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...

Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination ...

Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

Dr. Kirk Shepard (Chief Medical Officer) detailed a pivotal change to the Phase III VERSATILE-003 study design: “we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate ...

On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 2:20 PM EDTCompany ParticipantsLavina Talukdar - Senior VP & Head ...